12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Company News  |  Deals

Biogen Idec, Isis Pharmaceuticals deal

Isis granted Biogen Idec an exclusive, worldwide option to develop and commercialize antisense candidates against three undisclosed targets to treat neurological or neuromuscular disorders. Isis, which is responsible for discovery and development through the first Phase II trial for each of the programs, will receive a...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >